Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients

BACKGROUND: Following the PALOMA-3 study results, the combination of palbociclib, a CDK4/6 inhibitor, with fulvestrant, a selective estrogen receptor degrader, has become a standard therapy in women with estrogen receptor-positive (ER+) HER2-negative (HER2−) metastatic breast cancer (MBC). Palbocicl...

Descripción completa

Detalles Bibliográficos
Autores principales: Darrigues, Lauren, Pierga, Jean-Yves, Bernard-Tessier, Alice, Bièche, Ivan, Silveira, Amanda Bartolini, Michel, Marc, Loirat, Delphine, Cottu, Paul, Cabel, Luc, Dubot, Coraline, Geiss, Romain, Ricci, Francesco, Vincent-Salomon, Anne, Proudhon, Charlotte, Bidard, François-Clément
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937332/
https://www.ncbi.nlm.nih.gov/pubmed/33676547
http://dx.doi.org/10.1186/s13058-021-01411-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937332/
https://www.ncbi.nlm.nih.gov/pubmed/33676547
http://dx.doi.org/10.1186/s13058-021-01411-0

Ejemplares similares